Tolvaptan Treatment and Long-Term Impact on Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients: A Pilot Study

Clin Drug Investig. 2024 Apr;44(4):289-291. doi: 10.1007/s40261-024-01350-6. Epub 2024 Mar 2.

Affiliations

¹ Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy.
² Nephrology, Dialysis and Transplantation Unit, Department of Medicine, University of Padova, Via Giustiniani, 2, 35128, Padua, Italy. renzcalo@unipd.it.

^# Contributed equally.

PMID: 38430434
DOI: 10.1007/s40261-024-01350-6

No abstract available

Publication types

Letter

MeSH terms

Antidiuretic Hormone Receptor Antagonists / therapeutic use
Glomerular Filtration Rate
Humans
Kidney
Pilot Projects
Polycystic Kidney, Autosomal Dominant* / drug therapy
Quality of Life
Tolvaptan / therapeutic use

Substances

Tolvaptan
Antidiuretic Hormone Receptor Antagonists

Grants and funding

DOR n. 2208432/2022/University of Padova